XTNT Stock Forecast: Xtant Medical Holdings, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Xtant Medical Holdings, Inc. is $0.75. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 51 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Xtant Medical Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (93): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (14): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
XTNT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on XTNT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Sept 2026 | LUCID CAPITAL MARKETS | Initiates | Buy | — |
| 13 May 2026 | BTIG | Reiterates | Buy | — |
| 31 Mar 2026 | BTIG | Maintains | Buy | — |
| 11 Nov 2025 | BTIG | Maintains | Buy | — |
| 16 May 2024 | BTIG | Maintains | Buy | — |
| 5 Dec 2023 | BTIG | Initiates | Buy | — |
| 11 July 2023 | Craig-Hallum | Maintains | Buy | — |
| 26 Apr 2023 | Craig-Hallum | Initiates | Buy | — |
| 17 May 2019 | Maxim Group | Downgrade | Hold | — |
| 8 Dec 2016 | Maxim Group | Initiates | Buy | — |
| 30 Nov 2016 | Aegis Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for XTNT.
This page is one stock. Monday covers all of them.
XTNT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
XTNT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Xtant Medical Holdings, Inc. returned −67.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
XTNT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.3×
- Price / book
- 0.8×
- EV / EBITDA
- —
Cheaper than 86% of US stocks
Cheaper than 78% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 57.9%
- Operating margin
- −11.0%
- Net margin
- —
Higher than 71% of US stocks
Higher than 26% of US stocks
- Return on equity
- −36.5%
- Return on assets
- −7.6%
- Dividend yield
- —
Higher than 25% of US stocks
Higher than 29% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Xtant Medical Holdings, Inc. has a market value of $29.5M and an enterprise value of $46.6M.
Revenue in the twelve months to 30 June 2026: $109.5M. The latest quarter shrank 35.0% year on year.
Net income over the same four quarters: −$11.1M, a −10.2% net margin.
Diluted earnings per share, trailing twelve months: −$0.08.
Free cash flow in the twelve months to 30 June 2026: −$696K.
Xtant Medical Holdings, Inc. employs 151 people — $725K of revenue per employee.
Data provided by Twelve Data
XTNT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at XTNT’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Xtant Medical Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about XTNT
What is the XTNT stock price forecast for 2026-2027?
The median 12-month analyst price target for Xtant Medical Holdings, Inc. is $0.75, with estimates ranging from $0.5 to $1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is XTNT stock a buy right now?
Of the 3 analysts covering Xtant Medical Holdings, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xtant Medical Holdings, Inc. 51 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank XTNT?
As at 21 Nov 2026, Xtant Medical Holdings, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (93 of 100).
Will XTNT stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts is $0.75, and Ticker Nerd's factor model ranks Xtant Medical Holdings, Inc. 51 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the XTNT stock forecast for 2030?
No analyst covering Xtant Medical Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XTNT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.5 to $1 over the next 12 months.
How has XTNT stock performed over the past year?
Xtant Medical Holdings, Inc. returned -67.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Xtant Medical Holdings, Inc. do?
Xtant Medical Holdings, Inc. is a medical technology company that develops, manufactures, and markets regenerative medicine products and spinal implant systems for orthopedic and neurological surgeons. Its product portfolio includes orthobiologics, bone graft substitutes, biologic scaffolds, tissue-based products, and spinal fixation devices used in procedures involving spinal fusion, bone healing, and the treatment of complex spine and orthopedic conditions.
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. is a medical technology company that develops, manufactures, and markets regenerative medicine products and spinal implant systems for orthopedic and neurological surgeons. Its product portfolio includes orthobiologics, bone graft substitutes, biologic scaffolds, tissue-based products, and spinal fixation devices used in procedures involving spinal fusion, bone healing, and the treatment of complex spine and orthopedic conditions. The company also serves related surgical areas such as chronic wound care, sports medicine, cranial repair, and foot and ankle applications. Xtant Medical Holdings, Inc. focuses on products that support surgical reconstruction and biologic healing across domestic and international markets. Based in Belgrade, Montana, the company operates as a specialized supplier within the medical device and regenerative medicine sectors.
CEO Mr. Sean E. Browne · 151 employees · United States · https://xtantmedical.com